A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus
Status:
Completed
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy, safety, tolerability, and pharmacokinetics of oral GK
Activator (2), compared to placebo, in patients with type 2 diabetes mellitus. The
anticipated time on study treatment is less than 3 months, and the target sample size is
100-500 individuals.